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Plasma sphingosine-1-phosphate (S1P) regulates
vascular permeability, and plasma and lymph S1P
guide lymphocyte egress from lymphoid organs.
S1P is made intracellularly, and little is known about
how S1P is delivered into circulatory fluids. Here, we
find that mice without the major facilitator super-
family transporter Spns2 have a profound reduction
in lymph S1P, but only a minor decrease in plasma
S1P. Spns2-deficient mice have a redistribution of
lymphocytes from the spleen to lymph nodes and
a loss of circulating lymphocytes, consistent with
normal egress from the spleen directed by plasma
S1P and blocked egress from lymph nodes directed
by lymph S1P. Spns2 is needed in endothelial cells to
supply lymph S1P and support lymphocyte circula-
tion. As a differential requirement for lymph and
blood S1P, Spns2 may be an attractive target for
immune suppressive drugs.INTRODUCTION
The concentration of sphingosine-1-phosphate (S1P) is high in
circulatory fluids. Plasma S1P regulates vascular integrity; loss
of plasma S1P causes increased vascular permeability, likely
due to loss of signaling through S1P receptor 1 (S1PR1) on endo-
thelial cells (Camerer et al., 2009; Lee et al., 1999). Plasma and
lymph S1P guide lymphocyte egress from lymphoid organs
into circulation; exit requires an S1P gradient, low in the organ
parenchyma compared to the exit site, that is sensed by lympho-
cytes via S1PR1 (Schwab and Cyster, 2007). Although extracel-
lular S1P in tissues is thought to be low in homeostasis, an influx
of plasma S1P may be a powerful proinflammatory stimulus
(Rivera et al., 2008). FTY720, a drug recently approved for treat-
ment of multiple sclerosis, targets four of five S1P receptors
(Brinkmann et al., 2010). By inhibiting S1PR1 signaling in
lymphocytes, FTY720 traps activated cells in the draining lymph
nodes and prevents them from reaching the central nervous
system. FTY720 may, however, also target S1P signaling in
endothelial cells and cardiomyocytes, contributing to side
effects such as macular edema and bradycardia (Brinkmann
et al., 2010). To our knowledge, no differential requirements for1104 Cell Reports 2, 1104–1110, November 29, 2012 ª2012 The Autblood and lymph S1P have been reported to date. A major
goal of therapies that manipulate S1P signaling is to achieve
greater tissue selectivity.
Many questions remain about how S1P distribution is
controlled; one outstanding problem is how S1P, made intracel-
lularly by sphingosine kinases, is exported to the extracellular
space where it can signal through cell surface receptors. This
question is particularly interesting because S1P is thought to
be made by all cells as an intermediate in sphingolipid metabo-
lism; hence, export capacity may be a determinant of whether
this S1P is further metabolized, acts on intracellular targets, or
is used for cell-cell communication (Saba andHla, 2004). Several
ABC family transporters have been implicated in S1P secretion
in vitro. Knockdown or pharmacological inhibition of ABCC1
inhibits S1P export from vascular endothelial cells, mast cells,
MCF-7 breast cancer cells, skin fibroblasts, and rat myometrial
cells; knockdown or pharmacological inhibition of ABCG2 further
decreases S1P export from MCF-7 cells; deletion or pharmaco-
logical inhibition of ABCA1 limits S1P release from vascular
endothelial cells and astrocytes (Lee et al., 2007; Mitra et al.,
2006; Nieuwenhuis et al., 2009; Sato et al., 2007; Takabe et al.,
2010; Tanfin et al., 2011). However, neither Abcc1/ nor
Abca1/ mice have decreased plasma S1P (Lee et al., 2007).
The major facilitator superfamily member Spns2 enables extra-
cellular delivery of S1P, and zebrafish lacking this transporter
develop cardia bifida similar to animals lacking S1PR2; Spns2
may transport S1P from the yolk sac into the embryo body to
promote myocardial precursor migration to the midline (Kawa-
hara et al., 2009). Spns2 expression by endothelial cells has
recently been reported to promote egress of mature T cells
from the thymus, likely due to local secretion of S1P at the exit
site (Fukuhara et al., 2012; Hisano et al., 2012; Nijnik et al., 2012).
Here, we find that Spns2-deficient mice have a profound
reduction in lymph S1P, with only a minor change in plasma
S1P. Spns2-deficient mice have a redistribution of lymphocytes
from the spleen to lymph nodes and loss of lymphocytes in
circulation, consistent with normal egress from the spleen
directed by plasma S1P and blocked egress from lymph nodes
directed by lymph S1P. Spns2 is required in endothelial cells to
supply lymph S1P and support lymphocyte circulation.
RESULTS AND DISCUSSION
After confirming that murine Spns2 can export S1P (Figure S1),
we asked whether Spns2 is expressed in the cells that supplyhors
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Figure 1. Murine Spns2 Is Expressed by Endothelial Cells but Not RBC
(A) Expression of Spns2 mRNA by the indicated cell populations, expressed relative to hypoxanthine-guanine phosphoribosyltransferase (Hprt) transcript,
assessed by RT-qPCR. Ter119+CD71+ immature RBC (iRBC) were sorted from bone marrow; CD31+gp38+ lymphatic endothelial cells (LEC), CD4+CD62Lhi
T cells (CD4), CD8+CD62Lhi T cells (CD8), and CD19+CD62Lhi B cells (CD19) were sorted from lymph nodes. Data compile three experiments with mice on
a B6 background.
(B) Expression of Spns2 protein by the indicated cell populations, assessed by western blot. RBC were isolated from blood by differential centrifugation; CD31+
endothelial cells (EC) were isolated from heart and lung bymagnetic bead enrichment; andCD4+ T cells, CD8+ T cells, andCD19+ B cells were isolated from lymph
nodes by magnetic bead enrichment. Data are representative of three experiments with mice on a B6 background.
(C) Spns2-targeted allele. SA, splice acceptor; pA, polyadenylation signal.
(D–F) Efficiency of Spns2 deletion in Spns2f/fTie2-Cre+ mice. PCR for Spns2 exon 3 in genomic DNA from sorted Spns2f/fTie2Cre+(D) or littermate control (Ctrl)
cells (D). Littermate controls maintained one or two intact alleles of Spns2. RBC progenitors were isolated from bonemarrow. Hematopoietic stem and progenitor
cells (HSPC) were defined as Lin-IL7Ra-c-Kit+Sca1+; common myeloid progenitors (CMP) as Lin-IL7Ra-c-Kit+Sca1-FcgRloCD34+; and megakaryocyte erythroid
progenitors (MEP) as Lin-IL7Ra-c-Kit+Sca1-FcgRloCD34-. Lymphatic endothelial cells (LEC), defined as CD45-CD31+gp38+, and fibroblastic reticular cells (FRC),
defined as CD45-CD31-gp38+ were isolated from lymph nodes. Data are representative of at least two experiments. Spns2 mRNA assessed by RT-qPCR of
transcripts from sorted LEC and FRC (E). Data compile seven pairs of mice analyzed in seven experiments for LEC and three pairs of mice analyzed in three
experiments for FRC. NS, no signal. Spns2 protein assessed by western blot of mixed heart and lung endothelial cells (F). Data are representative of two
experiments. EC, endothelial cells.
See also Figure S1.circulatory S1P. These cells have been identified primarily by
lineage-specific deletion of the sphingosine kinases. Hemato-
poietic cells are the main source of plasma S1P, with red blood
cells (RBC) being a major contributor (Pappu et al., 2007). RBC
have lost most of their mRNA, but Spns2 transcript is scarce in
their immediate precursor reticulocytes (Figure 1A). Spns2
protein was undetectable in RBC (Figure 1B). Lymphatic endo-
thelial cells are the main source of lymph S1P (Pham et al.,
2010). Spns2 mRNA is robustly expressed by lymph node
lymphatic endothelial cells (Figure 1A), and Spns2 protein was
readily detected in endothelial cells (Figure 1B).
Based on these results, we hypothesized that if Spns2 were
important in secretion of circulatory S1P, itmight have a selective
role in supplying S1P to lymph. To test this, we obtained Spns2
mutant mice from the NIH Knockout Mouse Project. A splice
acceptor preceding exon 3 prematurely terminates the tran-
script, and we refer to this allele as Spns2tr. After flippase-
mediated recombination, the original sequence is restored
except that exon 3 remains flanked by loxP sites, and we refer
to this allele as Spns2f. After Cre-mediated recombination, the
loss of exon 3 results in a truncated nonfunctional proteinCell Re(Figure 1C). We crossed Spns2f/f animals with mice carrying
Cre recombinase under the Tie2 promoter, which is expressed
in hematopoietic and endothelial cells (Ficara et al., 2008;
Kisanuki et al., 2001; Srinivasan et al., 2007). In Spns2f/fTie2Cre+
mice, exon 3 of Spns2was efficiently deleted in genomic DNA of
hematopoietic stem cells, common myeloid progenitors, and
megakaryocyte-erythrocyte progenitors (RBC and reticulocytes
are anucleate), aswell as lymph node lymphatic endothelial cells,
but not lymph node fibroblastic reticular cells (Figure 1D).
Furthermore, Spns2 transcript was lost in Spns2
f/f
Tie2-Cre+
lymph node lymphatic endothelial cells but not lymph node
fibroblastic reticular cells (Figure 1E), and Spns2 protein was
lost in Spns2f/fTie2-Cre+ endothelial cells (Figure 1F). The loss
of Spns2 mRNA and protein was substantial but not complete
in Spns2tr/tr mice (data not shown); hence, for most experiments
we used Spns2f/fTie2-Cre+ animals.
We first assessed whether blood plasma S1P was altered
in Spns2-deficient mice. Tandem mass spectrometry measure-
ments revealed little reduction (23%) of plasma S1P in
Spns2f/fTie2-Cre+ mice compared to littermate controls (Fig-
ure 2A), similar to previous reports (Fukuhara et al., 2012; Hisanoports 2, 1104–1110, November 29, 2012 ª2012 The Authors 1105
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Figure 2. Spns2 Is Essential to Supply
Lymph S1P, but Makes aMinor Contribution
to Plasma S1P
(A–E) Spns2 makes a minor contribution to plasma
S1P. (A) Plasma S1P of Spns2f/fTie2-Cre+ (D) and
littermate control mice quantified by mass spec-
trometry (n = 6, error bars show SD). (B) Surface
S1PR1 on CD62LhiCD4+ T cells circulating in the
blood of a representative Spns2f/fTie2-Cre+mouse
(red) and its littermate control (black). Isotype
control is shaded gray; note that based on staining
of S1PR1 knockout animals, the isotype control
staining may be artificially low (Green et al., 2011
and data not shown). (C) The ratio of surface
S1PR1MFI on CD62LhiCD4+ T cells in the blood of
a Spns2f/fTie2-Cre+ or Spns2tr/tr (Tr) mouse to
surface S1PR1 MFI on CD62LhiCD4+ T cells in the
blood of its littermate control. Circles indicate
Spns2f/fTie2-Cre+ mice and controls (eight pairs
analyzed in seven experiments), and squares
indicate Spns2tr/tr mice and controls (three pairs
analyzed in three experiments). (D and E) Spns2f/fTie2-Cre+ or Spns2tr/tr and littermate control RBC were incubated with [3-3H]sphingosine (Sph), which crosses
the plasma membrane into the cytosol where it can be phosphorylated. After 90 min, the cell pellet (P) and supernatant (S) were collected. Extracted lipids were
separated by thin layer chromatography (TLC) to assess the distribution of [3-3H]S1P. A representative TLC plate visualized by Phosphorimager (D). Data pooled
from five experiments (E). Percent secreted S1P: 100 3 [S1P in supernatant]/[S1P in pellet + S1P in supernatant]. Circles indicate Spns2f/fTie2-Cre+ mice and
controls, and squares indicate Spns2tr/tr mice and controls.
(F–H) Spns2 is essential to supply lymph S1P.
(F) Lymph S1P of Spns2f/fTie2-Cre+ mice and littermate controls quantified by mass spectrometry (n = 2–3, error bars show SD).
(G) Surface S1PR1 on CD62LhiCD4+ T cells circulating in the lymph of a representative Spns2f/fTie2-Cre+ mouse (red) and its littermate control (black). Isotype
control is shaded gray.
(H) The ratio of surface S1PR1 MFI on CD62LhiCD4+ T cells in the lymph of a Spns2f/fTie2-Cre+ or Spns2tr/tr (Tr) mouse to surface S1PR1 MFI on CD62LhiCD4+
T cells in the lymph of its littermate control. Circles indicate Spns2f/fTie2-Cre+mice and controls (eight pairs analyzed in seven experiments), and squares indicate
Spns2tr/tr mice and controls (three pairs analyzed in three experiments). *p < 0.05, **p < 0.01et al., 2012; Nijnik et al., 2012). As a complementary measure of
S1P, we examined surface S1PR1 expression on naive T cells
circulating in blood; S1PR1 is exquisitely sensitive to ligand-
mediated internalization, and its surface expression has been
used extensively as a measure of cell exposure to S1P (Liu
et al., 1999; Pappu et al., 2007; Pham et al., 2010; Schwab
et al., 2005). Naive T cells in the blood exhibited similarly low
receptor levels in Spns2tr/tr mice, Spns2f/fTie2-Cre+ mice, and
littermate controls, suggesting that lymphocytes sense equiva-
lent S1P (Figures 2B and 2C). Consistent with near wild-type
plasma S1P levels in Spns2-deficient mice, Spns2-deficient
RBC secrete S1P normally (Figures 2D and 2E).
We next measured lymph S1P in Spns2-deficient mice.
Tandemmass spectrometry measurements revealed a dramatic
loss of lymph S1P in Spns2f/fTie2-Cre+ mice compared to litter-
mate controls (Figure 2F). Again, as a complementary measure
of S1P, we examined surface S1PR1 expression on naive
T cells in lymph. T cells in the lymph of Spns2tr/tr and Spns2f/f
Tie2-Cre+ mice expressed robust surface S1PR1 compared to
littermate controls (Figures 2G and 2H), suggesting that the
concentration of lymph S1P is very low in Spns2mutant animals.
We then turned to the effects of Spns2 deletion on lymphocyte
trafficking. Naive lymphocytes normally circulate among
secondary lymphoid organs surveying for antigen. Exit from
the spleen is guided by the high concentration of S1P in plasma
compared to the spleen. One indication of this gradient is that
surface S1PR1 is higher on lymphocytes in the spleen than in
blood; this difference is maintained in Spns2f/fTie2Cre+ mice1106 Cell Reports 2, 1104–1110, November 29, 2012 ª2012 The Aut(Figure 3A). Exit from lymph nodes is guided by the high concen-
tration of S1P in lymph compared to lymph nodes. Again, one
indication of this gradient is that surface S1PR1 is higher on
lymphocytes in lymph nodes than in lymph; this difference is
abolished in Spns2f/fTie2Cre+ mice (Figure 3A).
We predicted that in the presence of normal plasma S1P,
egress from the spleen would proceed as usual, but in the
absence of lymph S1P, egress from lymph nodes would be
blocked. Over time, this should lead to a redistribution of
lymphocytes from spleen to lymph nodes, as any cell that left
the spleen and entered a lymph node would be trapped in the
lymph node. This would also lead to a loss of circulating lympho-
cytes in blood and lymph. Spns2f/fTie2-Cre+mice had a reduced
percentage of total peripheral naive CD4 T cells in the spleen
compared to littermate controls (15% versus 42%), and recipro-
cally an increased percentage of total peripheral CD4 T cells in
the lymph nodes (85% versus 58%) (Figure 3B). Furthermore,
Spns2f/fTie2-Cre+ mice had a 24-fold reduction in CD4 T cells
circulating in blood, and a 10-fold reduction in CD4 T cells circu-
lating in lymph (Figure 3C). CD8 T cell redistribution in Spns2f/f
Tie2-Cre+ mice followed the same pattern (Figures 3D and 3E).
Consistent with previous findings that B cells have higher toler-
ance for disruption of S1P gradients (Pham et al., 2010; Schwab
et al., 2005), the effect on B cells was less dramatic, although it
showed the same trend (Figures 3F and 3G). Layered on top of
the lymphocyte redistribution in Spns2f/fTie2-Cre+mice, we
saw an overall reduction in lymphocyte numbers in the periphery
(Figure 3H). Part of this reduction may be due to inefficienthors
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Figure 3. Spns2 Is Required for Peripheral Lymphocyte Circulation
(A) Surface S1PR1 on CD62LhiCD4+ T cells in the blood and spleen (top panels) and in the lymph and lymph nodes (bottom panels) of a representative
Spns2f/fTie2Cre+ mouse (D) and its littermate control (Ctrl). Isotype control is shaded gray. Data are representative of eight pairs of mice analyzed in seven
experiments.
(B–G) Lymphocyte distribution in Spns2f/fTie2Cre+mice and littermate controls. Percent of total peripheral CD62LhiCD4+ T cells (B), CD62LhiCD8+ T cells (D), and
CD62LhiCD19+ B cells (F) in the spleen and lymph nodes (LN). Total peripheral lymphocytes are defined as those in spleen and a subset of LN (brachial, axillary,
inguinal, and mesenteric); blood and lymph make a negligible contribution. For example, (B, spleen) shows 100 3 (# CD62LhiCD4+ T cells in spleen)/
(# CD62LhiCD4+ T cells in spleen + #CD62LhiCD4+ T cells in LN). Data pool six pairs ofmice analyzed in five experiments. Total number of CD62LhiCD4+ T cells (C),
CD62LhiCD8+ T cells (E), andCD62LhiCD19+ B cells (G) in blood and lymph. Data pool eight pairs ofmice analyzed in seven experiments for blood, and five pairs of
mice analyzed in four experiments for lymph.
(H) Total number of CD62LhiCD4+ T cells, CD62LhiCD8+ T cells, and CD62LhiCD19+ B cells in the periphery. Data pool six pairs of mice analyzed in five
experiments.
(I) Vascular permeability in Spns2f/fTie2Cre+mice and littermate controls. Spns2-deficient mice and littermate controls, and C57BL6 mice treated with FTY720 or
vehicle, were injected intravenously with Evans Blue dye. After 90min, mice were perfused with PBS. Lungs were removed and extravasated Evans Blue dye was
quantified by spectrophotometry. Circles indicate Spns2f/fTie2-Cre+ mice and controls (six groups analyzed in six experiments), and squares indicate Spns2tr/tr
mice and controls (two groups analyzed in two experiments).
*p < 0.05, **p < 0.01. See also Figure S2.egress of mature T cells from the thymus in Spns2-deficient
animals (Figure S2; Fukuhara et al., 2012; Hisano et al., 2012;
Nijnik et al., 2012).Cell ReWe next asked whether the requirement for Spns2 to supply
lymph S1P and enable egress was intrinsic to endothelial cells.
Tie2-Cre deletes in both hematopoietic cells and endothelialports 2, 1104–1110, November 29, 2012 ª2012 The Authors 1107
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Figure 4. Spns2 Is Required in Endothelial Cells to Supply Lymph S1P and Support Lymphocyte Circulation
(A–E) Ubiquitin C:GFP+ mice were lethally irradiated and reconstituted with BM from Spns2-deficient mice or littermate controls (GFP+ mice were used to allow
assessment of RBC chimerism). Mice were analyzed > 6 weeks after transplantation, when RBC and circulating lymphocytes were 97%–99% donor-derived.
Deletion of Spns2 inSpns2f/fTie2Cre+ (D) donor hematopoietic stem and progenitor cells (HSPC) was confirmed by PCR. Data compile six pairs of recipients, with
two pairs of Spns2f/fTie2-Cre+/control BM donors (circles) and one pair ofSpns2tr/tr (Tr)/control BM donors (squares), analyzed in six experiments. Representative
histogram of surface S1PR1 on CD62LhiCD4+ T cells in the lymph and lymph nodes of the indicated chimeras (A). Isotype control is shaded gray. The
ratio of surface S1PR1 MFI on CD62LhiCD4+ T cells in the lymph of a WT mouse with Spns2-deficient BM to surface S1PR1 MFI on CD62LhiCD4+ T cells in the
lymph of a WT mouse with littermate control BM (B). Percent of total donor-derived peripheral CD62LhiCD4+ T cells in the spleen and lymph nodes (C). Total
number of donor-derived CD62LhiCD4+ T cells in blood and lymph (D). Total number of donor-derived CD62LhiCD4+ T cells in the periphery (E).
(F–J) Spns2f/fTie2-Cre+ mice and littermate controls were lethally irradiated and reconstituted with BM from Ubiquitin C:GFP+ mice. Mice were analyzed
> 6 weeks after transplantation, when RBC were 88%–99% donor-derived and lymphocytes were 85%–98% donor-derived. Data compile four pairs of mice
analyzed in four experiments. Representative histogram of surface S1PR1 on CD62LhiCD4+ T cells in the lymph and lymph nodes of the indicated chimeras (F).
Isotype control is shaded gray. The ratio of surface S1PR1MFI on CD62LhiCD4+ T cells in the lymph of a Spns2f/fTie2-Cre+mouse with WT BM to surface S1PR1
MFI on CD62LhiCD4+ T cells in the lymph of its littermate control with WT BM (G). Percent of total donor-derived peripheral CD62LhiCD4+ T cells in the spleen and
lymph nodes (H). Total number of donor-derived CD62LhiCD4+ T cells in blood and lymph (I). Total number of donor-derived CD62LhiCD4+ T cells in the periphery
(J). *p < 0.05, **p < 0.01.
See also Figures S3 and S4.cells, so to distinguish between the two we made bone marrow
(BM) chimeras. First, lethally irradiated wild-type (WT) mice were
reconstituted with Spns2-deficient or littermate control BM. We
found no reduction in lymph S1P or defect in lymphocyte traf-
ficking in WT mice with Spns2-deficient BM (Figures 4A–4E,
S3, and S4). In complementary experiments, Spns2f/fTie2Cre+
mice and littermate controls were reconstituted with WT BM. In
Spns2f/fTie2Cre+ mice with WT BM, lymph S1P remained low
and lymphocyte circulation impaired (Figures 4F–4J, S3, and
S4). These results are consistent with the requirement for the
sphingosine kinases in lymphatic endothelial cells rather than
hematopoietic cells to supply lymph S1P (Pham et al., 2010),
and with weak-to-undetectable expression of Spns2 in lympho-
cytes (Figures 1A and 1B).
Taken together, these data demonstrate that Spns2 expres-
sion by endothelial cells is essential for secretion of lymph
S1P, while Spns2 is dispensable for RBC secretion of plasma1108 Cell Reports 2, 1104–1110, November 29, 2012 ª2012 The AutS1P. A major goal in improving therapies that disrupt S1P
signaling is to achieve greater receptor and tissue specificity.
Although FTY720 is remarkably effective in multiple sclerosis,
at least in part because it inhibits exit of activated lymphocytes
from lymphoid organs and hence prevents them from reaching
the brain, FTY720 has serious vascular and cardiac side effects.
To our knowledge, no distinct factors necessary to supply lymph
and blood S1P have been identified to date. As a differential
requirement for lymph and blood S1P, Spns2 may be an attrac-
tive target for immune suppressive drugs that inhibit lymphocyte
egress while minimizing effects on vascular stability. In fact, we
found that there is little difference in lung vascular permeability
between Spns2-deficient and control animals, and Spns2-defi-
cient mice show decreased lung vascular permeability
compared to mice treated with FTY720 (Figure 3I). Future work
will assess whether Spns2 plays a similarly minor role in other
tissues and in inflammation.hors
As has been previously reported, we find that exit of mature
T cells from the thymus of Spns2f/fTie2-Cre+animals is inefficient
(Fukuhara et al., 2012; Hisano et al., 2012; Nijnik et al., 2012).
Although we cannot exclude a role of other Spns2 substrates
in promoting thymic egress, the defect is likely due to disruption
of the S1P gradient at the exit site, an interpretation supported by
the slight increase in S1PR1 levels on thymocytes of Spns2-
deficient mice (Figure S2). And although we cannot know
whether Spns2 plays as dominant a role in S1P export from
blood vessel endothelial cells in vivo as it does in lymphatic
endothelial cells, it is likely a significant contributor. Endothelial
cells have been reported to express several of the ABC trans-
porters implicated in S1P export by cultured cells, but how this
expression varies among subsets remains to be determined.
One fascinating question is why there is a loss of peripheral
lymphocytes in Spns2-deficient mice. The thymic egress block
may be a relatively small part of the explanation. Mice with
a similar accumulation of mature T cells in the thymus due to
disruption of S1P gradients, such as mice lacking lipid phos-
phate phosphatase 3 in thymic epithelial cells or mice lacking
sphingosine kinases in neural crest-derived thymic pericytes,
have a smaller reduction in peripheral T cell numbers than
Spns2-deficient mice (Bre´art et al., 2011; Zachariah and Cyster,
2010). By contrast, mice that lack lymph S1P due to ablation of
sphingosine kinases in lymphatic endothelial cells, which does
not affect thymic egress because mature T cells exit the thymus
into blood, have a similar reduction in peripheral lymphocyte
numbers to Spns2-deficient mice (Pham et al., 2010; Zachariah
and Cyster, 2010). Future studies will address whether the
decrease in overall lymphocyte number in the absence of lymph
S1P may reflect a role of S1P itself, or another factor that cells
receive during circulation, in promoting survival or homeostatic
proliferation (Oskouian and Saba, 2010).
Much work remains to be done to identify the transporters that
supply S1P in different tissues and disease states; they may be
excellent candidates for local regulation of S1P. As a differential
requirement for lymph and blood S1P, Spns2 is an attractive
target for specific spatial modulation of S1P signaling.EXPERIMENTAL PROCEDURES
Mice and Bone Marrow Chimeras
Spns2 mutant mice were obtained from the NIH Knockout Mouse
Project. b-Actin-FLPe (Rodrı´guez et al., 2000), Tie2-Cre (Kisanuki et al.,
2001), R26R-EYFP (Srinivas et al., 2001), and Ubiquitin C-GFP mice (Schae-
fer et al., 2001) were from Jackson laboratories. All mice were on a C57BL6
background. For bone marrow chimeras, recipients were irradiated with two
6.5 Gy doses of g irradiation from a cesium source separated by 3 hr, and
received 2-10 3 106 bone marrow cells by intravenous injection. Chimeras
were analyzed at least 6 weeks after transplantation. Mice were housed in
specific pathogen-free conditions at the Skirball Institute animal facility.
All animal experiments were performed in accordance with protocols
approved by the New York University Institutional Animal Care and Use
Committee.
Cell Preparation and Analysis
Cells were enriched either by magnetic beads (Stem Cell Technologies, biotin
selection kit, used according to the manufacturer’s instructions), flow cytom-
etry (Beckman Coulter MoFlo or BD Biosciences FACSAria), or differential
centrifugation. S1P export assay was adapted from (Olivera and Spiegel,Cell Re1998), vascular permeability assay was adapted from (Camerer et al., 2009),
and genomic PCR, reverse transcription followed by real-time quantitative
PCR (RT-qPCR), western blot, mass spectrometry, confocal microscopy,
and flow cytometry were performed using standard procedures. (Please see
Extended Experimental Procedures for detailed protocols.)
Statistics
All comparisons are by Student’s 2-tailed paired t test. When data are plotted
on a log-scale, log-transformed data are compared.
SUPPLEMENTAL INFORMATION
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